👨🔬 As a dedicated and experienced researcher, I work in academia to discover new treatments for seemingly incurable diseases. I previously investigated the pharmacology of drugs, and have now changed field to focus on understanding the molecular mechanisms that drive pathological states.
⚕️ My current research is within the Biffi Group, working to help identify treatments for pancreatic ductal adenocarcinoma (PDAC). I am especially focussed on chronic pancreatitis, which is a debilitating condition and a major risk factor for PDA.
My particular areas of expertise include 🐁 mouse models, etc...
Li W, Lehutová D, Sparidans RW, Heydari P, Wang J, Lebre MC,
Beijnen JH, Schinkel AH.
ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
Eur J Pharm Biopharm. 2022 Aug;177:135-146.
Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel
P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Int J Cancer. 2020 Mar 15;146(6):1631-1642.
Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Pharmacol Res. 2018 Nov;137:47-55.